Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

2018 Lung Cancer

Chouaid, C. | Bensimon, L. | Clay, E. | Millier, A. | Levy-Bachelot, L. | Huang, M. | Levy, P. | Volume: 127, Issue: , Pages: 44-52,

?Over a 5-year time-horizon, pembrolizumab improves LYs and QALYs vs. SoC chemotherapy.?The ICERs of pembrolizumab vs. SoC platinum-based chemotherapy were

https://www.doi.org/10.1016/j.lungcan.2018.11.008